Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250

被引:5
|
作者
Hendrickx, Baudewijn W.
Punt, Cees J. A.
Boerman, Otto C.
Postema, Ernst J.
Oosterwijk, Egbert
Mavridu, Agapi
Corstens, Frans H. M.
Oyen, Wim J. G.
机构
[1] Radboud Univ Nijmegen, Med Ctr, Dept Nucl Med 565, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, NL-6500 HB Nijmegen, Netherlands
[3] Radboud Univ Nijmegen, Med Ctr, Dept Urol, NL-6500 HB Nijmegen, Netherlands
[4] Wilex AG, Munich, Germany
关键词
cG250; radioimmunoscintigraphy; radioiodinated antibody; biliary cancer;
D O I
10.1089/cbr.2006.21.263
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Carbonic anhydrase 9 recognized by chimeric monoclonal antibody cG250 is overexpressed on biliary cancers. The aim of this study was to determine the targeting of radiolabeled cG250 in patients with biliary cancer to explore a potential role of radioimmunotherapy. Methods: Three (3) patients received a diagnostic dose In-111-cG250, and images were acquired 2 hours and 5 days after injection. Immediately after the last imaging session, I-131-cG250 was administered and images were acquired after 2 hours and 5 days. Visual and quantitative analyses was performed and tumor-to-background, tumor-to-normal liver-uptake ratios, and tumor uptake were calculated. Results: Administration of In-111-cG250 in patients with biliary cancer did not reveal enhanced uptake in the cancer lesions on whole-body scans. The scans obtained after the I-131-cG250 administration showed slightly enhanced tumor uptake in I patient with cholangiocarcinoma stage II. In 2 patients with gallbladder carcinoma stage TV, neither In-111-cG250 nor I-131-cG250 showed targeting of known tumor lesions. Immunohistochemical analysis demonstrated CA1X expression in all 3 cases. There were no adverse events related to radiolabeled cG250 administration. Conclusions: In-111- or I-131-labeled cG250 is not suitable for biliary cancer targeting. Therefore, there is no basis to develop radioimmunotherapy based on radiolabeled cG250 in biliary cancer.
引用
收藏
页码:263 / 268
页数:6
相关论文
共 50 条
  • [21] ImmunoPET imaging of renal cell carcinoma with 124I-and 89Zr-labeled anti-CAIX monoclonal antibody cG250
    Stillebroer, Alexander
    Franssen, Gerben
    Oyen, Wim
    Oosterwijk, Egbert
    Laverman, Peter
    Mulders, Peter
    Boerman, Otto
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [22] A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients
    M. Siebels
    K. Rohrmann
    R. Oberneder
    M. Stahler
    N. Haseke
    J. Beck
    R. Hofmann
    M. Kindler
    P. Kloepfer
    C. Stief
    World Journal of Urology, 2011, 29 : 121 - 126
  • [23] A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREXA®) and interferon-alpha-2a in metastatic renal cell carcinoma patients
    Siebels, M.
    Rohrmann, K.
    Oberneder, R.
    Stahler, M.
    Haseke, N.
    Beck, J.
    Hofmann, R.
    Kindler, M.
    Kloepfer, P.
    Stief, C.
    WORLD JOURNAL OF UROLOGY, 2011, 29 (01) : 121 - 126
  • [24] IMMUNOPET IMAGING OF RENAL CELL CARCINOMA WITH 124I-AND 89ZR-LABELED ANTI-CAIX MONOCLONAL ANTIBODY CG250
    Stillebroer, A.
    Franssen, G. M.
    Boerman, O. C.
    Oosterwijk, E.
    Laverman, P.
    Oyen, W. J. G.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 153 - 154
  • [25] A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients (pts) with advanced renal cell carcinoma (RCC).
    Davis, ID
    Liu, Z
    Saunders, W
    Lee, FT
    Spirkoska, V
    Hopkins, W
    Smyth, F
    Hoffman, EW
    Old, LJ
    Scott, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 177S - 177S
  • [26] PET/CT imaging of surgical specimens utilizing radiolabeled monoclonal 124I-cG250 antibody: An exploration of imaging histology
    Murrey, Douglas
    Hall, Nathan
    Bahnson, Eamonn
    Bahnson, Robert
    Martin, Edward
    Knopp, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50
  • [27] Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250
    Steffens, MG
    Boerman, OC
    OosterwijkWakka, JC
    Oosterhof, GON
    Witjes, JA
    Koenders, EB
    Oyen, WJG
    Buijs, WCAM
    Debruyne, FMJ
    Corstens, FHM
    Oosterwijk, E
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1529 - 1537
  • [28] ImmunoPET Imaging of Renal Cell Carcinoma with 124I- and 89Zr-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice
    Stillebroer, Alexander B.
    Franssen, Gerben M.
    Mulders, Peter F. A.
    Oyen, Wim J. G.
    van Dongen, Guus A. M. S.
    Laverman, Peter
    Oosterwijk, Egbert
    Boerman, Otto C.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2013, 28 (07) : 510 - 515
  • [29] Clinical evaluation of the distribution of two different radiolabeled injections of chimeric monoclonal antibody G250 in patients with primary RCC.
    Steffens, MG
    Boerman, OC
    Oosterwijk, E
    Oyen, WJG
    Witjes, JA
    Oosterhof, GON
    Debruyne, FMJ
    Corstens, FHM
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 246P - 247P
  • [30] INTERIM ANALYSIS OF A PHASE I RADIOIMMUNOTHERAPY STUDY IN ADVANCED RENAL CELL CARCINOMA PATIENTS USING LUTETIUM-177 LABELED MONOCLONAL ANTIBODY CG250
    Stillebroer, A.
    Oosterwijk, E.
    Boerman, O. C.
    Oyen, W. J. G.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185